Androgen receptor RTDTs

  • Target androgen receptor [AR] and co-target DNA
  • Therapeutic uses
    • aggressive AR-expressing tumors with high proliferation fraction including virtually all castrate resistant prostate cancers, refractory and recurrent ovarian cancers, and approximately 40% of triple-negative breast cancers
    • as an adjuvant to conventional therapy of AR-expressing tumors to kill cancer cells during the DNA repair process


  • Target BChE and co-target DNA
  • Therapeutic uses
    • ovarian cancer
    • high risk neuroblastoma with amplified N-MYC
    • glioblastoma
    • colorectal cancer, particularly hepatic metastases

survivor with child